News | May 16, 2014

Reference Pricing for Proton Therapy Will Help Establish Clinical Benefits

Radiation oncologists at Penn's Abramson Cancer Center say model will preserve access to technology and propel research

May 16, 2014 — Proton therapy is in the proverbial chicken or the egg scenario. Companies are pulling back on reimbursements to treat some cancers — notably prostate, breast and lung — because of the added expense and limited evidence to back it up. But in order to demonstrate the technology’s clinical benefit — which is showing promise as a more effective and better tolerated radiation — more studies with patients are needed. So which should come first?

Both, say Abramson Cancer Center physicians Justin E. Bekelman, M.D., an assistant professor of radiation oncology at the Perelman School of Medicine at the University of Pennsylvania, and Stephen M. Hahn, M.D., chair of radiation oncology. In an article published in the Journal of Clinical Oncology, the authors propose “reference pricing”— a relatively new model that establishes a standard price for different therapies with similar outcomes. It would expand the patient base because of increased, cheaper coverage and thus research to establish whether its novel advantages translate into clinical benefits.

In this case, proton therapy should be set at the less expensive rate currently paid for intensity-modulated radiation therapy (IMRT), which is covered under most insurance plans, and Medicare and Medicaid, the authors propose.

Having found success with this model with private insurers since it was implemented in 2010, the University of Pennsylvania Health System is leading the way for other centers — which are popping up around the country — to make other treatments options more accessible to patients while moving the field along even further.

“We want to be a responsible leader for both patients and payers,” said Bekelman. “This proposal does just that. This is an important and promising therapy for patients. We need to generate evidence to see whether proton therapy is better or equivalent to other modalities.”

Next month, the Health Technology Assessment Program (HTAP) in Washington state will decide whether and under what circumstances the state’s public payers will pay for proton therapy — a decision that could have powerful influence over payment policies of other payers in the U.S. health care system. The HTAP has a unique legislative mandate in the U.S. to evaluate health technologies and translate evidence of comparative and cost effectiveness into payment policy.

This examination of proton therapy comes at decisive moment, as major insurers have recently announced policies that restrict coverage for proton therapy for certain cancers.

“HTAP should not follow suit,” said Bekelman. “We propose a better way forward with reference pricing. By linking payment for proton therapy to evidence development, we echo prior calls to tie reimbursement for unproven technologies to the broad mandate of comparative effectiveness research with randomized trials.”

When compared to conventional radiation therapies, proton therapy stands to offer several benefits for patients who are candidates, including decreased radiation to normal tissues, decreased side effects and complications, and the ability to re-treat tumors after recurrences. Every day, more than 100 patients are treated at Penn Medicine's Roberts Proton Therapy Center. Several studies have shown such advantages, but what is lacking is randomized clinical trials.

Moving forward, the authors call for the HTAP to lead the way by deciding on behalf of its public payers to cover proton therapy under a policy of reference pricing with evidence development. They also call for a national proton therapy clinical trials consortium, led by physicians, and comprised of patients, payers, federal agencies and device manufacturers, to jump start, design and fund research-related costs for high-quality multi-center comparative effectiveness studies.

“The tradeoff is justifiable,” the authors write. “We will have reduced reimbursement, at least for a time, to promote evidence generation for a technology that or may not lead to better outcomes for great number of patients.”

“This will preserve access to the technology and renew efforts to conduct crucial research,” they add.

For more information: www.uphs.upenn.edu/news

Related Content

IBA Releases Razor Nano Ionization Chamber
News | Proton Therapy | September 22, 2017
September 22, 2017 — IBA (Ion Beam Applications S.A.) announced the release of the Razor Nano Chamber, the smallest a
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
The IBA Proteus Plus

The IBA Proteus Plus.

Feature | Proton Therapy | September 08, 2017 | By Jeff Zagoudis
As one of the more precise methods of delivering radiation therapy for cancer treatment, proton therapy has grown at a...
Penn Medicine to Host Fourth Annual Proton Therapy Training Course
News | Proton Therapy | August 30, 2017
August 30, 2017 — IBA (Ion Beam Applications S.A.) and the Department of Radiation Oncology at Penn Medicine, in part
Sponsored Content | Videos | Proton Therapy | August 21, 2017
Mark Pankuch, Ph.D., director of medical physics at the Northwestern Medicine Chicago Proton Center, discusses the cl
MedStar Georgetown Proton Center Selects RayStation for Treatment Planning
News | Treatment Planning | August 17, 2017
August 17, 2017 — The proton center at MedStar Georgetown University Hospital will utilize RayStation for planning on
DOSIsoft Releases ISOgray Proton Therapy Treatment Planning System
Technology | Treatment Planning | August 15, 2017
DOSIsoft SA announced the official release, with CE marking, of ISOgray Treatment Planning System (TPS) release 4.3 for...
Eight Proton Therapy Centers Worldwide Adopt RayStation for Treatment Planning
News | Treatment Planning | July 21, 2017
RaySearch Laboratories reported that eight additional proton therapy centers worldwide have recently chosen RayStation...
IBA to Install Proton Therapy Facility at Inova Schar Cancer Institute
News | Proton Therapy | July 18, 2017
IBA (Ion Beam Applications S.A.) and Inova recently signed a contract for a two-room Proteus Plus proton therapy...
Proton International and Beaumont Health Open Michigan's First Proton Therapy Facility
News | Proton Therapy | July 17, 2017
Proton International (PI) and Beaumont Health recently opened the state’s first proton therapy center, offering the...
Overlay Init